Reprogramming macrophage polarization via CD44-targeted and ROS-responsive apabetalone-loaded micelles for rheumatoid arthritis treatment
Current treatments for rheumatoid arthritis (RA) are highly limited by poor joint targeting, systemic toxicity, and an inability to precisely modulate the complex inflammatory microenvironment driven by overactive macrophages and elevated reactive oxygen species (ROS). To address these core challenges, this study devel...